Beijing, China, January 07 2021 — The first phase of the China Talents Training Program on Interventional Therapy for Arrhythmia and Electrophysiology Technology (“the Talents Program”), organized by Hainan Bo’ao R&D Center for Heart Health and Shanghai MicroPort® EP MedTech Co., Ltd. (“MicroPort® EP”), has recently been launched with a theoretical training session. The Talents Program was supported by experts from the Chinese Society of Pacing and Electrophysiology (CSPE) of Chinese Medical Association (CMA) and the Chinese Society of Arrhythmias (CSA), and attracted more than 3,200 people to watch and learn through live streaming.
The Talents Program, first created by MicroPort® EP in July 2020, has integrated expert resources from the CMA to provide professional trainings on interventional therapy for arrhythmia and electrophysiology technology for hospitals and doctors, aiming to strengthen the training and capacity development on electrophysiology therapy in primary hospitals.
Prof. Shu Zhang, from the Chinese Academy of Medical Sciences at Fuwai Hospital, who served as the first director of the Chinese Society of Arrhythmias（CSA）, said, “Only by continuously training excellent young surgeons and next-generation experts can we promote the development and progress of electrophysiology.”
During the training session, Prof. Min Tang from Chinese Academy of Medical Sciences at Fuwai Hospital gave a detailed orientation on the Talent Program, focusing on five “enhancements”: enhancing teaching materials, enhancing talent cultivation, enhancing teaching centers, enhancing treatment processes, and enhancing the effect of health economics. By offering a series of online and offline training activities including regional lecture tours, regional seminars, and regional demonstration centers, the Talents Program provides a platform for young technical talents in the field of cardiac electrophysiology in China to learn, exchange and demonstrate their work, as well as an opportunity to study in renowned medical centers at home and abroad.
At the conclusion of the training, President Xuebin Han of Shanxi Cardiovascular Hospital said, “We should call on more specialists to actively participate in the Talents Program. The program should build the capacity of a contingent of excellent and independent young physicians as soon as possible through a standardized and systematic electrophysiology training scheme.”
Dr. Yiyong Sun, President of MicroPort® EP, said, “We hope that by promoting the Talents Program, we can strengthen the training and capacity development on electrophysiological diagnosis and treatment in primary hospitals. This will contribute to the popularization of high-quality medical resources in local hospitals, and by extension, bridge the gap between supply and demand in the treatment of arrhythmia at the grassroots level, so that more patients have access to quality treatment. After over a decade of development, MicroPort® EP has become the only total solution provider of cardiac electrophysiology in China to date that covers a combination of active and passive techniques, as well as devices and equipment. We look forward to working with more doctors to provide patients with quality, inclusive, and integrated solutions with health economics advantages.”
In 2021, the Talents Program will further consolidate the expert resources of the Society in 2021 to support the growth of primary hospitals and doctors through regular theoretical lectures, regional hands-on trainings, and training center programs that cover overseas and domestic institutes.
About Arrhythmia:
Arrhythmia is the leading cause of sudden cardiac death. According to data from the Report of the Study on the Status of the Epidemiology of Arrhythmia, there are over 10 million patients with arrhythmias in China. In the future, more than 1.5 million patients are expected to undergo radiofrequency ablation procedures in China annually. However, according to the Arrhythmia Interventional Therapy Registry of Mainland China 2019, only 170,000 radiofrequency ablation procedures were performed in China in 2019, by only 800 physicians who were capable of performing such procedures independently—far from sufficient to meet patients’ needs.